This study, called TETON-PPF, is looking at how safe and effective inhaled treprostinil is for people with progressive pulmonary fibrosis (PPF) and interstitial lung disease (ILD). Inhaled treprostinil is given using a special nebulizer. You could be eligible if you are at least 18 years old and have radiological evidence of pulmonary fibrosis. The study aims to see if inhaled treprostinil can improve your lung function, specifically your forced vital capacity (FVC), over 52 weeks. This study is currently recruiting about 698 participants, but its exact status is unclear.

Study design

This is a Phase 3, multinational, randomized, double-blind, placebo-controlled study. About 698 participants will be randomly assigned to receive either inhaled treprostinil or a placebo.

What's involved

You would take the inhaled treprostinil or placebo four times a day, starting with 3 breaths and increasing to a target of 12 breaths as tolerated. You would have 6 clinic visits over 52 weeks at Weeks 4, 8, 16, 28, 40, and 52.

Compensation

Not stated in the trial record.

Follow-up

The primary endpoint measures changes in lung function from baseline to Week 52.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.